Aliskiren/amlodipine
Combination of
AliskirenRenin inhibitor
AmlodipineCalcium channel blocker (dihydropyridine)
Clinical data
Trade namesTekamlo, Rasilamlo
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
  • C in first trimester;
    D in second and third trimesters
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
 ☒NcheckY (what is this?)  (verify)

The drug combination aliskiren/amlodipine (INNs, trade names Tekamlo and Rasilamlo) is an antihypertensive. Clinical trials have shown it to be more effective than amlodipine on its own,[1] with a high dosing regime (aliskiren 300 mg/amlodipine 10 mg) being more effective than olmesartan/amlodipine with comparable tolerability.[2]

References

  1. ^ Pfeiffer D, Rennie N, Papst CC, Zhang J (November 2012). "Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy¥". Current Vascular Pharmacology. 10 (6): 773–80. doi:10.2174/157016112803520945. PMID 22303911.
  2. ^ Axthelm C, Sieder C, Meister F, Kaiser E (January 2012). "Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg". Current Medical Research and Opinion. 28 (1): 69–78. doi:10.1185/03007995.2011.637914. PMID 22117838. S2CID 25693979.

Further reading

External links

Antihypertensive drugs acting on the renin–angiotensin system (C09)
More
Categories